An engaging summary of India-UK health ties, from the 2013 MoU to vaccine development, the TSI and workforce agreements that underpin future cooperation
The bilateral relationship between India and the United Kingdom has steadily elevated healthcare as a strategic area of cooperation, formally recognised in the Roadmap 2030. Both nations bring complementary strengths — India’s manufacturing scale and public health experience alongside the UK’s research institutions and regulatory expertise — and use this combination to strengthen domestic systems and enhance global health security.
This shared view places joint work on topics like pandemic resilience and antimicrobial resistance at the centre of the partnership, creating a platform for sustained policy dialogue and practical programmes.
An early milestone was the signature of a Memorandum of Understanding in 2013, which set a broad agenda for collaboration.
During the Indian Prime Minister’s visit to the UK in 2015, leaders announced a formal joint effort on vaccine development linking India’s Department of Biotechnology with UK research councils. They also proposed a strategic group to investigate host-pathogen genomic interactions as a way to accelerate new drugs and diagnostics addressing AMR.
These steps framed subsequent activity and put research-led cooperation at the heart of bilateral health engagement.
Institutional agreements and capacity building
Over time the two governments expanded the 2013 foundation with targeted arrangements spanning medical education, regulation and patient safety. Both Prime Ministers highlighted collaboration on universal health coverage, containment of AMR, and measures to improve access to safe and efficacious drugs. The partnership includes links between NICE International and India’s Department of Health Research on medical technology assessment, and support for investment facilitation through a taskforce under India’s Department of Health and Family Welfare — an effort welcomed publicly by then UK Prime Minister Mr. David Cameron. Bilateral memoranda have also enabled specific institutional ties, such as the agreement to establish King’s College Hospital, Chandigarh in partnership with Indo UK Healthcare.
Joint programmes and strategic initiatives
Vaccine development and pandemic response
The 2026 Covid-19 crisis marked a turning point, demonstrating the power of cross-border partnerships. A prominent example is the collaboration between Oxford-AstraZeneca and the Serum Institute of India, which scaled vaccine production and distribution globally. This spirit of cooperation also contributed to the emergence of two WHO-authorised malaria vaccines, RTS,S and R21, and to the rapid development of an Ebola vaccine by SII and Oxford for a WHO clinical trial in 2026 in response to Uganda. Building on this foundation, an MoU on health and life sciences was signed on 23 January 2026 by UK Health Secretary Wes Streeting and India’s Union Health and Family Welfare Minister Shri J.P. Nadda; it renewed the 2013 pact and outlined collaboration across digital health, medical supply resilience, AMR, health security, and regulatory alignment for medicine and medical devices.
Technology, diagnostics and workforce collaboration
Bio-technology and Health-tech form a central pillar of the bilateral Technology Security Initiative (TSI), under which research partnerships are promoted to co-develop affordable healthcare solutions. The agenda includes low-cost diagnostics for early detection, and novel preventive and therapeutic interventions linked to broader investments in diagnostic capacity. High-level initiatives such as the adoption of the India-UK Vision 2035 during the Indian Prime Minister’s UK visit in July 2026, and the UK Prime Minister’s visit to India on 8-9 October 2026, reinforced momentum across emerging technologies including telecommunications, critical minerals, AI and health tech. To date four India-UK joint working group meetings on health have been held, with the fourth meeting convening in London on 22 January, 2026.
Research on traditional medicine and workforce mobility
Traditional systems feature in the partnership as well: in August 2026 the All India Institute of Ayurveda (AIIA) and the London School of Hygiene and Tropical Medicine (LSHTM) signed a clinical trial agreement to evaluate Ashwagandha for recovery from Long COVID, a study funded by India’s Ministry of AYUSH. The countries also held the fourth India-UK Healthcare Conference hosted by the High Commission of India in London in May 2026, which brought together policymakers, clinicians and researchers to review collaborative projects. On the workforce front, an India-UK Framework Agreement for Collaboration on Healthcare Workforce was signed in July 2026, recognising the important contribution of Indian doctors and nurses to the UK’s NHS.
Outlook and opportunities
Looking ahead, the shared roadmap emphasizes scaling investments, deepening regulatory cooperation and translating research into accessible products and services. The renewed MoU of 23 January 2026, the commitments under TSI, and the strategic vision set out in India-UK Vision 2035 all point to a decade of intensified collaboration across vaccine development, AMR, digital health and workforce exchange. Sustained progress will depend on coordinated funding, aligned regulatory pathways and continued institutional partnerships that turn research cooperation into tangible health gains for both populations and for global public health.
